Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Defactinib |
Synonyms | |
Therapy Description |
Defactinib (VS-6063) inhibits FAK, resulting in decreased downstream signaling, and potentially leading to reduced tumor cell proliferation and survival (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Defactinib | VS-6063|PF-04554878 | FAK inhibitor 13 | Defactinib (VS-6063) inhibits FAK, resulting in decreased downstream signaling, and potentially leading to reduced tumor cell proliferation and survival (PMID: 31739184). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | lung non-small cell carcinoma | not applicable | Defactinib | Phase I | Actionable | In a Phase I trial, 31% (17/55) of KRAS-mutant patients with non-small cell lung cancer demonstrated progression-free survival at 12 weeks and one patient experienced a partial response and eight patients had stable disease as a best overall response when treated with Defactinib (VS-6063) (PMID: 31739184; NCT01778803). | 31739184 |
Unknown unknown | Advanced Solid Tumor | not applicable | Defactinib | Phase I | Actionable | In a Phase I trial, Defactinib (VS-6063) treatment demonstrated safety in patient with advanced solid tumors (PMID: 26334219). | 26334219 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01870609 | Phase II | Defactinib | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | Terminated | USA | CAN | 13 |
NCT02465060 | Phase II | Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Recruiting | USA | 2 |
NCT04331041 | Phase II | Defactinib | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | Not yet recruiting | USA | 0 |
NCT01951690 | Phase II | Defactinib | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02004028 | Phase II | Defactinib | Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma. | Terminated | USA | 0 |
NCT02943317 | Phase I | Defactinib Avelumab | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | Terminated | USA | 0 |
NCT03287271 | Phase Ib/II | Defactinib | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | Recruiting | USA | 0 |